Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5281000
Max Phase: Preclinical
Molecular Formula: C26H40N4O8
Molecular Weight: 386.54
Associated Items:
ID: ALA5281000
Max Phase: Preclinical
Molecular Formula: C26H40N4O8
Molecular Weight: 386.54
Associated Items:
Canonical SMILES: COCC(C)(C)CN1CCC(NC(=O)c2nn(C(C)C)c3ccccc23)CC1.O=C(O)C(O)C(O)C(=O)O
Standard InChI: InChI=1S/C22H34N4O2.C4H6O6/c1-16(2)26-19-9-7-6-8-18(19)20(24-26)21(27)23-17-10-12-25(13-11-17)14-22(3,4)15-28-5;5-1(3(7)8)2(6)4(9)10/h6-9,16-17H,10-15H2,1-5H3,(H,23,27);1-2,5-6H,(H,7,8)(H,9,10)
Standard InChI Key: KNVAWRMRVWVMHG-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 386.54 | Molecular Weight (Monoisotopic): 386.2682 | AlogP: 3.48 | #Rotatable Bonds: 7 |
Polar Surface Area: 59.39 | Molecular Species: BASE | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 9.07 | CX LogP: 2.66 | CX LogD: 0.99 |
Aromatic Rings: 2 | Heavy Atoms: 28 | QED Weighted: 0.79 | Np Likeness Score: -1.33 |
1. Nirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Ravella SR, Bogaraju N, Middekadi VR, Subramanian R, Palacharla RC, Benade V, Muddana N, Abraham R, Medapati RB, Thentu JB, Mekala VR, Petlu S, Lingavarapu BB, Yarra S, Kagita N, Goyal VK, Pandey SK, Jasti V.. (2021) Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease., 64 (15.0): [PMID:34251799] [10.1021/acs.jmedchem.1c00703] |
Source(1):